Company Profile
Eli Lilly Stock Price, News & Analysis
- Ticker:
- LLY
- Exchange:
- NYSE
- Sector:
- Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs
- Location:
- United States
Stock performance
1,197.53 USD (+0.13%)
Close
Last updated: July 27, 2026
949B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, LLY was little changed and closed at $1197.53. No new same-company headline was identified in the current news window.
Company overview
Business overview
Eli Lilly is a large-cap pharmaceutical company with major exposure to obesity, diabetes, neuroscience, and immunology. The company has become one of the market’s clearest growth stories thanks to its metabolic franchise and broad pipeline.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, Lilly is a global pharma company with a strong commercial presence across major markets. Its investor identity is built around growth, execution, and blockbuster product momentum.
Business Model Characteristics
Lilly combines blockbuster product revenue with a deep late-stage pipeline and major manufacturing investment. Investors watch demand, supply expansion, pipeline progress, and whether the company can keep scaling its metabolic and specialty franchises.
Position Within the Biotechnology Landscape
Lilly sits at the top tier of large-cap healthcare because it has both scale and strong growth visibility. Compared with smaller biotech names, the stock is less binary but still highly sensitive to launch execution and pipeline durability.
Future catalysts
Eli Lilly’s next catalysts are still centered on orforglipron, obesity and diabetes filing progress, and retatrutide development and manufacturing readiness. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Eli Lilly (LLY)?
Eli Lilly (LLY) most recently closed at 1,197.53 USD, a +0.13% move versus the previous session.
What is the market cap of Eli Lilly (LLY)?
Eli Lilly currently has a market capitalization of 949B USD on BioPharmSignal.
What does Eli Lilly do?
Eli Lilly is a large-cap pharmaceutical company with major exposure to obesity, diabetes, neuroscience, and immunology. The company has become one of the market’s clearest growth stories thanks to its metabolic franchise and broad pipeline.
On which exchange is LLY stock listed?
Eli Lilly (LLY) is associated with NYSE, United States, Biopharma, mRNA Vaccines, Vaccines, Oncology, Small Molecule Drugs.
What is Lilly?
Eli Lilly’s next catalysts are still centered on orforglipron, obesity and diabetes filing progress, and retatrutide development and manufacturing readiness.
Which conditions is Eli Lilly targeting with Lilly?
Eli Lilly is associated with immunology, metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Eli Lilly describe recent progress with Lilly?
Eli Lilly’s next catalysts are still centered on orforglipron, obesity and diabetes filing progress, and retatrutide development and manufacturing readiness.
What future catalysts are investors watching for Eli Lilly?
Eli Lilly’s next catalysts are still centered on orforglipron, obesity and diabetes filing progress, and retatrutide development and manufacturing readiness. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the...